AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06531317 — intervention group
Intervention type: DEVICE
Intervention: transcranial Direct Current Stimulation
Description: The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).
Study NCT06531317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography
Description: 64-channel active-electrode EEG with impedances kept \~5KOhm
Study NCT05052398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PSP NEURO SERUM
Description: PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands, three times a day.
Study NCT05052398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PSP NEURO SERUM
Description: Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
Study NCT05197088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 1 week of tamsulosin
Study NCT06434662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride liposome
Description: Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks
Study NCT06434662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks
Study NCT06434662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
Study NCT06546904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence empowers anesthesia with ultrasound assistance
Description: Artificial intelligence empowers anesthesia with ultrasound assistance
Study NCT06404632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lev-g
Description: Lev-g includes three sessions + a booster session using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev-g is done in groups to enable support and tips from others.
Study NCT01089205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01089205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT06457698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-puncture TMJ arthrocentesis under local anaesthesia
Description: The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.
Study NCT06457698 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Double-puncture TMJ arthrocentesis under local anaesthesia
Description: The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.
Study NCT06276166 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05270655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention
Description: Participants in the experimental group will receive five sessions of cognitive-behavioural intervention. Each session will be conducted face-to-face for 30-35 minutes a week and supplemented by home-based practices. The first session is an introductory to cognitive-behavioural intervention, the second session includes identifying, evaluating and challenging maladaptive thoughts, beliefs and behaviour, the third session includes behavioural activation, the fourth session is deep breathing, and the last session includes treatment evaluation and relapse prevention. The interventions will be delivered before chemotherapy sessions to avoid fatigue and to increase the patient's engagement with the interventions. To establish a strong therapeutic alliance and enhance intervention delivery and family support, parents will be invited to attend the introduction of the first session and the summary of each session (the last five minutes).
Study NCT05071014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: 200mg/dose delivered by IV infusion
Study NCT05071014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided cryoablation
Description: Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
Study NCT05036967 — intervention group
Intervention type: DRUG
Intervention: HF medication
Description: Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
Study NCT06267079 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: core stability exercise
Description: Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).
Study NCT00930995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: 16mg po daily
Study NCT00930995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT04710706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy insertion technique used during procedure
Description: Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
Study NCT06370156 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.
Study NCT06198244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation(TENS)
Description: Defecation frequency per week, abdominal pain or discomfort, type of stool, severity of the constipation, frequency and consistency of stool, were measured before the commencement of treatment by using Romes-IV criteria, Visual Analogue Scale (VAS),Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS).After taking the measurements apply TENS on abdomen i.e. on the lower gastrointestinal tract, placed two skin electrodes of TENS on the abdomen lateral to the umbilicus and other two electrodes on back side at T9-L2 level for a month (20 minutes per session and 3 times a week) along with baseline treatment in which general movements were performed. After the completion of treatment same tools were used to re-assess the defecation frequency per week, abdominal pain or discomfort, type of stool, and severity of the constipation, frequency and consistency of stool for the measurement of final reading(Pre and post-treatment).
Study NCT05503043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
Study NCT05503043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients are received equal volumes of saline intravenously until the end of the surgery
Study NCT05728528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
Description: combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
Study NCT05728528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Description: pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Study NCT05129618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MHS 1031
Description: prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides
Study NCT05129618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
Study NCT04658511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
Study NCT06198244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Treatment
Description: In control group, after the recruitment of participants according to the inclusion criteria. The baseline measurement were recorded by using Romes-IV criteria, Visual Analogue Scale (VAS), Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS). The baseline treatment is given in which general movements were performed i.e. Double knee-to-chest movement, sitting, standing, rolling as well as stretching of calf, hamstrings, adductors of both sides. Again assess the patient severity of constipation, frequency and consistency of stool, abdominal pain and functional status after the end of last session of the treatment(Pre and Post-treatment method).
Study NCT06196489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted vaping cessation intervention
Description: Behavioral intervention for vaping cessation
Study NCT05466045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil application in hemodialysis patients with pruritus
Description: Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
Study NCT05466045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline application in hemodialysis patients with pruritus
Description: Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
Study NCT04660110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPT with Dihydroartemisinin Piperaquine
Description: A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
Study NCT05107700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stay at altitude 2500 m above sea level (high altitude)
Description: Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
Study NCT05107700 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stay at altitude 2500 m above sea level (high altitude)
Description: Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
Study NCT05107700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stay at altitude 470 m above sea level (low altitude)
Description: Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
Study NCT05107700 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stay at altitude 470 m above sea level (low altitude)
Description: Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
Study NCT04855019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder periarticular injection, suprascapular and axillary nerve block
Description: In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance.
Study NCT05169411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure
Description: The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
Study NCT05169411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine protein
Description: Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
Study NCT04942782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbopelvic stabilization exercises
Description: the patients will receive lumbopelvic stabilization in the form of three parts: 1 Segmental control over primary stabilizers (mainly TrA, deep multifidus, pelvic floor and diaphragm) 2-Exercises in closed chain, with low velocity and low load 3-Exercises in open chain, with high velocity and load
Study NCT04942782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise
Description: the patient will receive pilates exercise in the form of Breast stroke prep, Side leg lift series, One leg circle, Hundreds, Shoulder bridge, and Spine stretch forward
Study NCT04942782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance
Study NCT04942782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance
Study NCT05102552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPN-817, Treatment B
Description: SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Study NCT05102552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPN-817, Treatment C
Description: SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Study NCT05102552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIS-001, Treatment A
Description: BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Study NCT06469606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI tool
Description: Both the arms will undergo the use of AI tool developed in the group. The tool will be trained to detect outcomes.
Study NCT06469528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Low dose daily colchicine
Study NCT05695924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioBridge® Collagen Matrix
Description: BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
Study NCT05695924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized Lymph Node Transfer (VLNT)
Description: Micro-surgical procedure for vascularized lymph node transfer (VLNT)
Study NCT05695924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vascularized Lymph Node Transfer (VLNT)
Description: Micro-surgical procedure for vascularized lymph node transfer (VLNT)
Study NCT05258929 — intervention group
Intervention type: OTHER
Intervention: Data collection (Prior and planned treatments, allograft)
Description: MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
Study NCT05739409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LILRB4 STAR-T cells injection
Description: The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
Study NCT06395532 — intervention group
Intervention type: OTHER
Intervention: Observetional
Description: After admission to the ICU, patients will be continuously monitored with ICU standard monitoring in addition to IPI using (Capnostream™ Medtronic). IPI will be recorded after transfer to the ICU, as well as at 2, 6, 12, 18 and 24 hours.
Study NCT05150522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cells
Description: BCMA CAR-T cells infusion
Study NCT06233097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole magnesium dihydrate-Test product
Description: Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
Study NCT06233097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole magnesium dihydrate-Reference product
Description: Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
Study NCT02436954 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CO2 insufflation at intra-abdominal pressure 8 mmHg
Description: insufflation of CO2 gas into peritoneum for maintaining the pressure of 8 mmHg
Study NCT02436954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 insufflation at intra-abdominal pressure 12 mmHg
Description: insufflation of CO2 gas into peritoneum for maintaining the pressure of 12 mmHg
Study NCT05784298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity rTMS
Description: 40 hz, 150 gauss, 1 session that lasts 45 minutes.
Study NCT05784298 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low-intensity rTMS
Description: 40 hz, 150 gauss, 1 session that lasts 45 minutes.
Study NCT05278832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: QLS31905 injection
Study NCT05575232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application Group (GA)
Description: The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.